Global Relapsing Multiple Sclerosis (RMS) - API Manufacturers, Marketed and Phase III Drugs Landscape 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The ‘Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018’ report provides comprehensive insights about marketed and Phase III products for Relapsing Multiple Sclerosis (RMS). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Relapsing Multiple Sclerosis (RMS)
Coverage of API manufacturers for Relapsing Multiple Sclerosis (RMS) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
Emerging Phase III products for Relapsing Multiple Sclerosis (RMS)
This report provides a comprehensive understanding of the emerging Phase III therapies for Relapsing Multiple Sclerosis (RMS) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
Key Topics Covered:
1. Report Introduction
2. Relapsing Multiple Sclerosis (RMS): OverviewRisk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed TherapiesProduct Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities United States Europe Historical Global Sales Forecasted Global Sales
5. Emerging Therapies (Phase III)Product Description Research and Development Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/x8tftf/global_relapsing?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005368/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 08:03 AM/DISC: 12/19/2018 08:03 AM